Clinical Utility of LC-MS/MS for Blood Myo-Inositol in Patients with Acute Kidney Injury and Chronic Kidney Disease
Clinical Chemistry · 2024
DOI: 10.1093/clinchem/hvae097 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Chemistry, 2024. Verfasst von Catherine L Omosule und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology & Immunology, Washington University School of Medicine, St. Louis, MO, United States. Hauptthemen laut MEDLINE: Renal Insufficiency, Chronic, Tandem Mass Spectrometry, Acute Kidney Injury, Inositol. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 45 Literaturangaben. Gefördert von: Barnes-Jewish Hospital Foundation.
Abstract (Originalsprache)
Background
Diagnosing acute kidney injury (AKI) and chronic kidney disease (CKD) relies on creatinine, which lacks optimal diagnostic sensitivity. The kidney-specific proximal tubular enzyme myo-inositol oxygenase (MIOX) catalyzes the conversion of myo-inositol (MI) to D-glucuronic acid. We hypothesized that proximal tubular damage, which occurs in AKI and CKD, will decrease MIOX activity, causing MI accumulation. To explore this, we developed an LC-MS/MS assay to quantify plasma MI and assessed its potential in identifying AKI and CKD patients.
Methods
MI was quantified in plasma from 3 patient cohorts [normal kidney function (n = 105), CKD (n = 94), and AKI (n = 54)]. The correlations between MI and creatinine were determined using Deming regression and Pearson correlation and the impact of age, sex, and ethnicity on MI concentrations was assessed. Receiver operating characteristic curve analysis was employed to evaluate MI diagnostic performance.
Results
In volunteers with normal kidney function, the central 95th percentile range of plasma MI concentrations was 16.6 to 44.2 µM. Age, ethnicity, and sex showed minimal influence on MI. Patients with AKI and CKD exhibited higher median MI concentrations [71.1 (25th percentile: 38.2, 75th percentile: 115.4) and 102.4 (77, 139.5) µM], respectively. MI exhibited excellent sensitivity (98.9%) and specificity (100%) for diagnosing CKD. In patients with AKI, MI increased 32.9 (SD 16.8) h before creatinine.
Conclusions
This study unveils MI as a potential renal biomarker, notably elevated in plasma during AKI and CKD. Plasma MI rises 33 h prior to serum creatinine, enabling early AKI detection. Further validation and exploration of MI quantitation in kidney disease diagnosis is warranted.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pathology & Immunology, Washington University School of Medicine, St. Louis, MO, United States.
- Department of Pediatrics, Washington University School of Medicine, St. Louis, MO, United States.
- Department of Medicine (Nephrology), Washington University School of Medicine, St. Louis, MO, United States.
ORCID-Profile: Catherine L Omosule, Christopher Farnsworth
Förderung
- Barnes-Jewish Hospital Foundation
Zitieren
APA
Omosule, C. L., Blair, C. J., Herries, E., Zaydman, M. A., Farnsworth, C., Ladenson, J., Dietzen, D. J., & Gaut, J. P. (2024). Clinical Utility of LC-MS/MS for Blood Myo-Inositol in Patients with Acute Kidney Injury and Chronic Kidney Disease. Clinical Chemistry. https://doi.org/10.1093/clinchem/hvae097
Vancouver
Omosule CL, Blair CJ, Herries E, Zaydman MA, Farnsworth C, Ladenson J, et al. Clinical Utility of LC-MS/MS for Blood Myo-Inositol in Patients with Acute Kidney Injury and Chronic Kidney Disease. Clinical Chemistry. 2024. doi:10.1093/clinchem/hvae097
BibTeX
@article{Omosule2024,
author = {Omosule, Catherine L and Blair, Connor J and Herries, Elizabeth and Zaydman, Mark A and Farnsworth, Christopher and Ladenson, Jack and Dietzen, Dennis J and Gaut, Joseph P},
title = {Clinical Utility of LC-MS/MS for Blood Myo-Inositol in Patients with Acute Kidney Injury and Chronic Kidney Disease},
journal = {Clinical Chemistry},
year = {2024},
doi = {10.1093/clinchem/hvae097}
}
EUVIMED